terbutaline sulphate

Beta2–adrenoceptor agonist: Reversible airways obstruction

Oral: 2.5–5 mg 3 times daily SC/IM/IV: 250–500 micrograms up to 4 times daily

: 90–300 micrograms/hour Turbohaler: 500 micrograms (1 inhalation) up to 4 times daily Nebulisation: 5–10 mg 2–4 times daily, or more frequently

Molecular weight : 548.6

%Protein binding : 15–25

%Excreted unchanged in urine : 55–60

Volume of distribution (L/kg) : 0.9–1.5

half-life – normal/ESRD (hrs) : 16–20/–

20 to 50 : 50% of normal parenteral dose. Other routes Dose as in normal renal function

10 to 20 : 50% of normal parenteral dose. Other routes. Dose as in normal renal function

<10 : Avoid parenteral dose. Other routes Dose as in normal renal function

CAPD : Likely dialysability. Dose as in GFR <10 mL/min

HD : Likely dialysability. Dose as in GFR <10 mL/min

HDF/high flux : Likely dialysability. Dose as in GFR <10 mL/min

CAV/VVHD : Likely dialysability. Dose as in GFR 10 to 20 mL/min

Potentially hazardous interactions with other drugs Effect may be diminished by beta-blockers Theophylline: increased risk of hypokalaemia

–

IV, SC, IM, oral, inhaled, nebulised

1.5–5 mcg/minute

For

, add 1.5–2.5 mg to 500 mL glucose 5% or sodium chloride 0.9% (3–5 micrograms/mL)